Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Aerosol Inhalation of MSC Exosomes in Healthy Volunteers
NCT04313647Phase 1Completed
- Sponsor
- Ruijin Hospital
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cell exosomes in acute respiratory distress syndrome (ARDS), pneumonia and chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Ruijin Hospital. Primary endpoint: Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE). Started Mar 2020; status: completed.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
acute respiratory distress syndrome (ARDS)pneumoniachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04313647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313647.